基于部分水解的瓜尔 (Sunfiber®) 的多组件计划对韩国血糖控制的影响:单臂前后比较试点临床试验
Hyoung Su Park1, A-Hyun Jeong2, Hyejung Hong3
1Leader, R&D Group, Maeil Health Nutrition Co., Ltd, Pyeongtaek, Korea.
Korean journal of community nutrition
|October 1, 2025
概括
一项为期六周的计划,结合了部分化瓜尔 (PHGG) 补充剂,营养指导和持续的葡萄糖监测,改善了韩国成年人的血糖控制,肠道健康和营养状况.
科学领域:
- 营养科学 营养科学
- 代谢健康 代谢健康
- 胃肠病学 胃肠病学
背景情况:
- 快餐血葡萄糖 (FPG) 的升高是糖尿病预防和管理的一个关注点.
- 饮食干预在改善代谢健康方面发挥着至关重要的作用.
- 部分化瓜尔 (PHGG) 是一种可溶性纤维,对肠道和代谢健康有潜在的益处.
研究的目的:
- 评估多组件计划对韩国成年人血糖控制,肠道健康和营养状况的影响.
- 评估在综合性干预中补充部分化 guar gum (PHGG) 的疗效.
主要方法:
- 一个为期六周的单臂试验,涉及29名成年人 (年龄20-55岁),FPG≥100 mg/dL.
- 参与者接受了PHGG (Sunfiber®,12.5克/天),每周接受营养指导,并使用连续血糖监测设备.
- 血糖控制 (FPG,HbA1c),肠道健康 (韩国肠道系数测量表) 和营养状况 (营养系数) 在干预前和后被评估.
主要成果:
- 在坚持参与者 (n=17) 中观察到FPG (113.06-106.24 mg/dL) 和HbA1c (6.08%-5.87%) 的显著降低.
- 所有参与者的综合营养分数和平衡/实践领域分数显著增加 (P <0.05).
- 大约82.1%的参与者报告了肠道健康的积极变化.
结论:
- 包括PHGG,饮食管理和健康监测设备在内的多组件干预措施显著改善了FPG升高的成年人的血糖控制.
- 该计划对整体营养状况和肠道健康产生了积极影响.
- 这种干预措施对糖尿病预防和管理策略有前途.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
525
01:06Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
01:17Oral Hypoglycemic Agents: Sulfonylureas
781
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
781
01:23Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594